Everything below concerns evidence base. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The end of the Cold War allowed many technologies that had been off limits to the public to be declassified. The most important of these is the Internet, which was created as ARPANET as a system to keep in touch after an impending nuclear war. The last restrictions on commercial enterprise online were lifted in 1995. The commercialization of the Internet and the growth of the mobile phone system increased globalization (as well as nationalism and populism in reaction). In the years since then, the Internet's population and usefulness have grown immensely. Only about 20 million people (less than 0.5 percent of the world's population at the time) were online in 1995, mostly in the United States and several other Western countries. By the mid-2010s, more than a third of the world's population was online. Further research continued into other Cold War technologies with the declassification of the Internet. While Ronald Reagan's Strategic Defense Initiative proved untenable in its original form, the system lives on in a redesigned state as the Aegis Ballistic Missile Defense System (BMDS). Countermeasures such as BMDS continue to be explored and improved upon post–Cold War, but are often criticized for being unable to effectively stop a full nuclear attack. Despite advances in their efficacy, anti-ballistic missiles are often viewed as an additional piece to modern day diplomacy where concepts such as mutual assured destruction and treaties such as that between Ronald Reagan and Mikhail Gorbachev following their Reykjavík Summit.
== Varieties == A wide variety of types and flavors of tofu is available in both Western and Eastern markets. Despite the range of options, tofu products can be split into two main categories: 'fresh tofu', which is produced directly from soy milk, and 'processed tofu', which is produced from fresh tofu. Tofu production also creates important by-products that are used in various cuisines.
== Stanford Research Institute == In 1962, Finnigan and one of his coworkers, physicist and nuclear engineer P. Michael Uthe Jr., left Livermore to work for the Stanford Research Institute (SRI) in Palo Alto, California. Finnigan was hired to establish a process controls group in SRI's control systems lab. SRI did contract research projects for both business and the military. One of the projects underway at SRI, led by Kenneth R. Shoulders, was developing a quadrupole mass spectrometer. Finnigan saw the potential for using the quadrupole broadly as a detector for instrumentation and process-control, and began trying to find support for its development and commercialization.
=== Nutrition === Neon tetras are omnivores and will accept most flake foods, if sufficiently small, but should also have some small foods such as brine shrimp, daphnia, freeze-dried bloodworms, tubifex, which can be stuck to the side of the aquarium, and micropellet food to supplement their diets. A tropical sinking pellet is ideal, as most brands of these include natural color enhancers that bring out the color in neon tetras. Some frozen foods, including frozen blood worms, add variety to their diets.
Sources: en.wikipedia.org
== History of discovery == Profilin was first described by Lars Carlsson in the lab of Uno Lindberg and co-workers in the early 1970s as the first actin monomer binding protein. It followed the realization that not only muscle, but also non-muscle cells, contained high concentrations of actin, albeit in part in an unpolymerized form. Profilin was then believed to sequester actin monomers (keep them in a pro-filamentous form), and release them upon a signal to make them accessible for fast actin polymer growth.
=== Pharmacogenetics === The predominant enzyme responsible for metabolism of tacrolimus is CYP3A5. Genetic variations within CYP3A5 that result in changes to the activity of the CYP3A5 protein can affect concentrations of tacrolimus within the body. In particular, individuals who are homozygous for the G allele at the single nucleotide polymorphism (SNP) rs776746 (also known as CYP3A5 *3/*3) have a non-functional CYP3A5 protein. The frequency of the G allele varies worldwide, from 4% in some African populations to 80–90% in Caucasian populations. Across a large number of studies, individuals homozygous for the G allele have been shown to have higher concentrations of tacrolimus and require lower doses of the drug, as compared to individuals who are not homozygous for the G allele. Achieving target concentrations of tacrolimus is important – if levels are too low, then there is a risk of transplant rejection, if levels are too high, there is a risk of drug toxicities. There is evidence to suggest that dosing patients based on rs776746 genotype can result in faster and more frequent achievement of target tacrolimus levels. However, there is a lack of consistent evidence as to whether dosing based on rs776746 genotype results in improved clinical outcomes (such as a decreased risk for transplant rejection or drug toxicities), likely because patients taking tacrolimus are subject to therapeutic drug monitoring. Studies have shown that genetic polymorphisms of genes other than CYP3A5, such as NR1I2 (encoding PXR), also significantly influence the pharmacokinetics of tacrolimus.
===== Sixth generation ===== Sixth generation breast implants were introduced in the early 2010s to address some of the issues seen in previous generations. They feature a smoother surface that is designed to minimize the body's inflammatory response and reduce the risk of a foreign body reaction. These implants use a newer, biomimetic topography that helps to reduce bacterial growth and inflammation compared to the earlier macro-textured devices. Additionally, they incorporate other advancements, such as ergonomic gels that change shape depending on body position and advanced multi-layered shells to reduce the diffusion of silicone. Some manufacturers have also introduced lightweight alternatives that use hollow microspheres mixed with silicone gel to make the implants lighter for a given volume. This has led to improved results, with studies showing that the implants form thinner capsules and cause less inflammation than their predecessors.
Sources: en.wikipedia.org
The oldest known parish register in Paris belongs to the parish of Saint-Jean-en-Grève. In agenda format and written in Latin, it covers the period from April 1515 to November 1521. Registers of baptisms were opened as early as 1525 in the parishes of Saint-André-des-Arts and Saint-Jacques-la-Boucherie. The first burial registers, from Saint-Josse and Saint-Landry, date back to 1527. In August 1539, Francis I issued the Ordinance of Villers-Cotterêts, requiring parish priests to keep a register of baptisms conducted in their church, written in French (Article 51):
== Research == Mechler has contributed to the field of materials science through his work on self-assembling systems, lipid membranes, biophysical chemistry, antimicrobial peptides, and metallosupramolecular systems.
If a stepparent legally adopts the partner's child or children, he or she becomes the child's legal parent. In such cases, the parents may stop using the terms stepparent and stepchild and instead refer to the child simply as their son or daughter; depending on the child's degree of affinity for the adoptive parent and/or approval of the legal proceedings culminating in the child's adoption, the child may likewise drop the "step-" designation from his or her description of the relationship. Even when all parties describe the relationship using the terms applied to biological and adoptive families, however, at least some of the emotional and psychological issues common to stepfamilies may or may not persist. Thus, one possibility is that a stepfamily can be reconfigured, and thanks to the biological and adoptive links could leave the condition of a stepfamily.
=== Modern standard === Third generation TSH assay is the requirement for modern standards of care. TSH testing in the United States is typically carried out with automated platforms using advanced forms of immunometric assay. Nonetheless, there is no international standard for measurement of thyroid-stimulating hormone.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.